Project CBD
AUGUST 6, 2019
Harvard University scientist Staci Gruber shared encouraging results from “the first open-label to double-blind clinical trial” assessing the impact of a high- CBD , low- THC sublingual tincture in patients who experience moderate anxiety. Results highlight the need for expanded patient access to CBD products.”.
Project CBD
AUGUST 6, 2019
Harvard University scientist Staci Gruber shared encouraging results from “the first open-label to double-blind clinical trial” assessing the impact of a high- CBD , low- THC sublingual tincture in patients who experience moderate anxiety. Results highlight the need for expanded patient access to CBD products.”.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cannigma
DECEMBER 12, 2022
Turning down activity in the DMN allows better access to new areas of the brain, which can boost creativity and improve problem solving. Hallucinations, increased blood pressure, nausea, vomiting, and diarrhea are all common side effects. Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety.
Veriheal
JUNE 29, 2022
The study was conducted by COMPASS Pathways , a mental healthcare company that is “dedicated to accelerating patient access to evidence-based innovation in mental health.” While 233 participants might sound low, it is still the largest number of humans to participate in a psilocybin-based clinical trial.
Veriheal
SEPTEMBER 6, 2022
During the third stage of sleep, muscles start to relax, and both the blood pressure rate and breathing rate drop. Clinical trials and placebo-controlled studies are needed to confirm the findings found in this review. During this particular part of sleep, the brain starts producing sleep spindles.
Expert insights. Personalized for you.
218 
Let's personalize your content